September 2010 Br J Cardiol 2010;17:209 Meeting report
The National Institute for Health and Clinical Excellence (NICE) has published new guidance on the management of chronic heart failure. This updates and replaces the previous guideline in this area (NICE clinical guideline 5)....
September 2010 Br J Cardiol 2010;17:211-14
News from the world of cardiology. ...
September 2010 Br J Cardiol 2010;17:215-16
We continue our series in which Consultant Interventionist Dr Michael Norell takes a sideways look at life in the cath lab…and beyond. In this column, he considers communication with the patient....
September 2010 Br J Cardiol 2010;17:220-21 Meeting report
Welcome to the first of a regular series of news and reviews from the British Cardiovascular Society (BCS). Many of you will already be BCS members and so the Society felt our readers would be interested in a regular update on BCS activities. In this first column, Dr Charles Knight, Honorary Secretary of the BCS, gives an overview of the Society and its role in advancing cardiovascular medicine in the UK....
September 2010 Br J Cardiol 2010;17:219
Correspondence from the world of cardiology...
July 2010 Br J Cardiol 2010;17:168-170 Meeting report
Renal denervation (RDN) revisited A novel, catheter-based technique is looking promising for the treatment of refractory hypertension. Renal sympathetic hyperactivity is associated with the development of hypertension and its progression, as well as chronic kidney disease (CKD) and heart failure. While sympathectomy procedures have been considered over the past 50 or more years, it is now possible, using a steerable femoral 6F catheter with an RF energy electrode tip, to deliver a series of 2 minute ablations to the renal artery, causing renal denervation (RDN) and blood pressure reduction. ...
July 2010 Br J Cardiol 2010;17:163-5
The National Institute for Health and Clinical Excellence (NICE) has published a new guidance on prevention of cardiovascular disease at the population level. ...
July 2010 Br J Cardiol 2010;17:163-5
A trial testing testosterone gel in older men with mobility limitations has been stopped early because of an increased risk of cardiovascular events in the treated group. ...
July 2010 Br J Cardiol 2010;17:163-5
A study of a new drug for atrial fibrillation, apixaban (Pfizer/Bristol-Myers Squibb), has been stopped early because of benefit....
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits